REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.
Pharmacology, Toxicology and Pharmaceutical Science
1
1%
Nursing and Health Professions
1
1%
Other
2
3%
Unknown
27
38%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 June 2024.
All research outputs
#2,891,015
of 27,145,244 outputs
Outputs from Journal of Clinical Oncology
#7,356
of 24,884 outputs
Outputs of similar age
#54,128
of 346,763 outputs
Outputs of similar age from Journal of Clinical Oncology
#125
of 596 outputs
Altmetric has tracked 27,145,244 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 24,884 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 346,763 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 596 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.